169
Views
1
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLES: ADENOMYOSIS

A clinical observational study on the efficacy of subcutaneous etonogestrel implants for adenomyosis in 20 patients

ORCID Icon, , , , , , & ORCID Icon show all
Pages 735-739 | Received 04 Jan 2021, Accepted 24 Apr 2021, Published online: 23 Jun 2021

References

  • Maheshwari A, Gurunath S, Fatima F, et al. Adenomyosis and subfertility: a systematic review of prevalence, diagnosis, treatment and fertility outcomes. Hum Reprod Update. 2012;18(4):374–392.
  • Munro MG. Uterine polyps, adenomyosis, leiomyomas, and endometrial receptivity. Fertil Steril. 2019;111(4):629–640.
  • Levy G, Dehaene A, Laurent N, et al. An update on adenomyosis. Diagn Interv Imaging. 2013;94(1):3–25.
  • Marnach ML, Laughlin-Tommaso SK. Evaluation and management of abnormal uterine bleeding. Mayo Clin Proc. 2019;94(2):326–335.
  • Dessouky R, Gamil SA, Nada MG, et al. Management of uterine adenomyosis: current trends and uterine artery embolization as a potential alternative to hysterectomy. Insights Imaging. 2019;10(1):48.
  • Vannuccini S, Luisi S, Tosti C, et al. Role of medical therapy in the management of uterine adenomyosis. Fertil Steril. 2018;109(3):398–405.
  • Isley M. Implanon: the subdermal contraceptive implant. J Pediatr Adolesc Gynecol. 2010;23(6):364–367.
  • Blumenthal PD, Gemzell-Danielsson K, Marintcheva-Petrova M. Tolerability and clinical safety of Implanon. Eur J Contracept Reprod Health Care. 2008;13(Suppl. 1):29–36.
  • Margatho D, Carvalho NM, Bahamondes L. Endometriosis-associated pain scores and biomarkers in users of the etonogestrel-releasing subdermal implant or the 52-mg levonorgestrel-releasing intrauterine system for up to 24 months. Eur J Contracept Reprod Health Care. 2020;25(2):133–140.
  • Funk S, Miller MM, Mishell DR Jr., et al. Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel. Contraception. 2005;71(5):319–326.
  • Higham JM, O'Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. BJOG. 1990;97(8):734–739.
  • Zakherah MS, Sayed GH, El-Nashar SA, et al. Pictorial blood loss assessment chart in the evaluation of heavy menstrual bleeding: diagnostic accuracy compared to alkaline hematin. Gynecol Obstet Invest. 2011;71(4):281–284.
  • Belsey EM, Machin D, d'Arcangues C. The analysis of vaginal bleeding patterns induced by fertility regulating methods. World Health Organization Special Programme of Research, Development and Research Training in Human Reproduction. Contraception. 1986;34(3):253–260.
  • Ferrero S, Scala C, Ciccarelli S, et al. Treatment of rectovaginal endometriosis with the etonogestrel-releasing contraceptive implant. Gynecol Endocrinol. 2020;36(6):540–544.
  • Flaherty SA. Pain measurement tools for clinical practice and research. AANA J. 1996;64(2):133–140.
  • Makarainen L, van Beek A, Tuomivaara L, et al. Ovarian function during the use of a single contraceptive implant: Implanon compared with Norplant. Fertil Steril. 1998;69(4):714–721.
  • Bennink HJ. The pharmacokinetics and pharmacodynamics of Implanon, a single-rod etonogestrel contraceptive implant. Eur J Contracept Reprod Health Care. 2000;5(Suppl. 2):12–20.
  • Fraser IS, Weisberg E, Minehan E, et al. A detailed analysis of menstrual blood loss in women using Norplant and Nestorone progestogen-only contraceptive implants or vaginal rings. Contraception. 2000;61(4):241–251.
  • Mansour D, Korver T, Marintcheva-Petrova M, et al. The effects of Implanon on menstrual bleeding patterns. Eur J Contracept Reprod Health Care. 2008;13(Suppl. 1):13–28.
  • Grandi G, Barra F, Ferrero S, et al. Hormonal contraception in women with endometriosis: a systematic review. Eur J Contracept Reprod Health Care. 2019;24(1):61–70.
  • Wu J, Huang Y, Chen L, et al. Treatment of adenomyosis with subcutaneous etonogestrel implants: a clinical observational study in 17 patients. Med Sci Monit. 2018;24:6085–6092.
  • Wong S, Naresh A. Etonogestrel subdermal implant-associated regression of endometrial intraepithelial neoplasia. Obstet Gynecol. 2019;133(4):780–782.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.